New York University Clinical Cancer Center | ClinicalTrials HQ

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer	hormone receptor-positive breast cancer	Recruiting	Phase 2	2026-07-16		NCT05467891
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)	Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Non-Melanoma Skin Neoplasms, Skin and Connective Tissue Diseases, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, cutaneous melanoma, lung disorder, lung neoplasm, melanocytic neoplasm, melanoma, mismatch repair cancer syndrome 1, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, primitive neuroectodermal tumor, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm	Active, not recruiting	Phase 2	2026-02-13		NCT03767348
Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)	Neoplasms by Site, Thoracic Neoplasms, lung cancer, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm	Active, not recruiting	Phase 2	2026-01-02		NCT04367311
Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients	Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder	Active, not recruiting	Phase 2	2026-01-02		NCT03393845